Crispr Therapeutics AG vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while First Trust NASDAQ 100 Technology Index Fund trades at $315.63. The key difference: First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | QTEC | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $76.78 | $335.74 |
52-Week Low | $44.34 | $207.03 |
Enterprise Value | $3.65B | — |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →